대한골관절종양학회지 (The Journal of the Korean bone and joint tumor society)
- 제12권1호
- /
- Pages.37-46
- /
- 2006
- /
- 1226-4962(pISSN)
- /
- 2233-9841(eISSN)
진행된 장관골 골육종의 수술 및 비수술적 강력 집속 초음파 치료의 장기 추적 결과
Clinical Outcome of Treatment for Stage IIA, IIB and III Osteosarcomas (Comparative Studies between Invasive Surgical Treatment and Non-invasive HIFU Technique)
- ;
- ;
- ;
- ;
- ;
- ;
- ;
- ;
- ;
- ;
-
이승구
(가톨릭대학교 의과대학 정형외과) ;
-
강용구
(가톨릭대학교 의과대학 정형외과) ;
- 박원종 (가톨릭대학교 의과대학 정형외과) ;
-
정양국
(가톨릭대학교 의과대학 정형외과) ;
- 허성우 (가톨릭대학교 의과대학 정형외과) ;
- 이은상 (가톨릭대학교 의과대학 정형외과)
- Wenzhi, Chen (Chonquing University of Medical Science) ;
- Wei, Wang (Beijing 307 Hospital, Academy of Military Medical Science) ;
- Zhibiao, Wang (Chonquing University of Medical Science) ;
- Hui, Zhu (Chonquing University of Medical Science) ;
- Kequan, Li (Chonquing University of Medical Science) ;
- Hao, Piao Xiang (Chonquing University of Medical Science) ;
- Haibing, Su (Chonquing University of Medical Science) ;
- Chengbing, Jin (Chonquing University of Medical Science) ;
- Feng, Wu (Chonquing University of Medical Science) ;
- Jin, Bai (Chonquing University of Medical Science) ;
-
Rhee, Seung-Koo
(Catholic University of Medical College) ;
-
Kang, Yong-Koo
(Catholic University of Medical College) ;
- Bahk, Won-Jong (Catholic University of Medical College) ;
-
Chung, Yang-Guk
(Catholic University of Medical College) ;
- Huh, Sung-Woo (Catholic University of Medical College) ;
- Lee, Eun-Sang (Catholic University of Medical College)
- 발행 : 2006.06.30
초록
목적: 장관골의 골육종 치료로써 한국에서 시행된 항암제 치료 및 수술적 치료 후의 결과와, 중국에서 시행된 비침습적인 초음파 치료(high intensity focused ultrasound, HIFU)간의 다국적 임상 결과를 비교하고자 한다. 대상 및 방법: 한국에서 1993년 이래로 통상적인 항암요법과 사지구제술을 시행한 총 67예(IIA; 4 cases, IIB; 58 cases, III; 5 cases)와, 중국에서 1997년 이래로 초음파 치료를 시행한 총 71예(II; 57 cases, III; 14 cases)를 연구 대상으로 하였다. 한국에서는 총 67예 중, 66예에서 수술 전 선행 화학치료를, 반면 중국에서는 총 71예 중, stage II의 34예에서 9회 이상의 full protocol 화학치료가 시행되었고, stage II의 23예와 stage III의 14예에서 8회 이하의 부분 화학치료를 시행하였다. 한국의 67예는 모두 광범위 절제술을 시행하였고, 56예에서 국소 재건술을 병행하였다. 5예에선 국소 재건 없이 광범위 절제만 시행하였고, 6예에선 절단술만을 시행하였다. 반면 중국의 총 71예는 평균 1.5회(1~4회)의 초음파 치료가 시행되었다. 결과: 한국의 stage II의 5년 생존율은 평균 92.7%(IIA 100%, IIB 85.5%), 반면, 중국의 5년 생존율이 평균 78.7%로써 항암제를 병행한 군은 91.8% 및 항암제 치료를 못 받은 군은 56.6%였다. Stage III의 3년 생존율은 한국 20%(5예중 1예 생존), 중국은 7.1%(14예 중 1예 생존)였으며, 전 예의 평균 생존율은 한국 65.2%, 중국 51.8%였다(Table 2). 한국 환자들의 ISOLS에 의한 최종 기능 평가 결과는 평균 24.3(81%)였고, 중국 환자들은 19.8(73%)였으며, 치료의 합병증은 한국 25.4%(17/67 cases), 중국 31%였다. 결론: 한국에서 시행한 수술적 치료전후 화학요법을 시행한 결과는 초음파 치료를 이용한 비침습적 열괴사 방법보다 양호하였으나, 골종양에 대한 초음파 치료도 적응증을 잘 선택한다면 장관골 골육종의 치유 및 국소 재발율을 감소시킬 수 있을 것으로 생각한다.
Purpose: To evaluate the end results between the surgical treatment with neo-adjuvant chemotherapy in Korea and non-invasive high intensity focused ultrasound (HIFU) technique in China for osteogenic sarcomas. Materials and Methods: The surgical treatment with neoadjuvant chemotherapy for total 67 cases (4 IIA, 58 IIB, and 5 III) in Korea since 1993 and the HIFU therapy for total 71 cases (57 II and 14 III) in China since 1997 was performed. In Korea, neo-adjuvant chemotherapy in 66 cases out of total 67 patients, but the adjuvant chemotherapy in only one case was done. On the contrary, in China, full chemotherapy for more than 9 times for 37 patients with stage II out of total 71 cases, but for less than 8 times of partial chemotherapy for 23 patients (stage II) and 14 patients (stage III) was done. The surgical treatment in total 67 Korean patients was done with wide resection and reconstruction for 56 patients, but wide resection without reconstruction for 5 patients and amputation for 6 patients. In china, total 71 patients was treated with average 1.5 times (1~4 times) of HIFU, and if there are some evidences of residual tumor after HIFU with following MRI, the second HIFU therapy was given 2~4 weeks later. After then, the bony defect was in no touch, keep bracing for long time expecting regeneration. All of them were followed for average 46 Mo (12~150 Mo) in Korea, but followed for average 22 Mo (9 years~8 months) in China. Results: The 5 year survival rate (stage II), was average 92.7% (IIA 100%, IIB 85.5%) in Korea series, and average 78.7% (full chemotherapy 91.8%, part chemotherapy 56.6%) in China series. The 3 year survival rate (stage III) was 20% in Korea and 7.1% in China. So, the final overall survival rate was 65.2% in Korea and 51.8% in China. The overall functional outcome score by ISOLS was 24.3 (81%) in Korea and 19.8 (73%) in China. There are 25.4% (17/67 cases) of complications in Korea and 31% (27 complications in 22 patients out of total 71 cases) in China after each treatment. Conclusions: The end results of Korea series which was treated with neoadjuvant chemo- and surgical methods are better than that of non-invasive thermal ablation in china. But we also believe the HIFU, as one of, was also effective to decrease the local recurrence and symptomatic releaf for stage II or even in III of osteogenic sarcomas.
키워드